Project Grant R41AI181391
Award Date 9/23/25
Completion Date 8/31/26
Dollars Obligated $314K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
North Carolina, USA
Similar Awards
- This Project Grant award, funded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855), provides $303,173 to Gateway Bio Inc. to develop a novel stealth lipid formulation for use in an HIV vaccine targeting the membrane-proximal external region (MPER) of the HIV envelope. The goal is to address a key challenge that led to the previous HVTN 133 clinical trial being halted - a polyethylene...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $392,714 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Cornell University to develop lipid nanoparticles (LNPs) for improving endosomal escape and reducing reactogenicity of nucleic acid-based therapies. The research aims to enhance the cytoplasmic release and reduce inflammatory responses of LNPs through novel ionizable lipid designs, including pH-switchable pyridine...
- This federal Project Grant award of $350,000 from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to develop polymer-derived biomaterials for messenger RNA (mRNA) delivery to induce antigen-specific immune tolerance. The award supports research to evaluate diverse nanocarrier formulations encapsulating antigens and mRNAs encoding tolerogenic proteins, investigate the biodistribution and...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $300,000 Project Grant under the Allergy and Infectious Diseases Research (CFDA 93.855) program to Optimeos Life Sciences, Inc., a biotechnology company in New Jersey. The grant supports the development of an off-the-shelf nanoparticle platform for in vivo stem cell gene therapy to treat severe immune deficiencies such as ADA-SCID. The project aims to deliver a DNA payload in nanoparticles targeting hematopoietic stem...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $676,666 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), for the project "Spatial and Temporal Adjuvant Delivery for Skin mRNA Vaccination". The goal of this project is to determine whether intranasal or intradermal delivery of a newly developed adjuvant can expand the breadth...
- This $300,000 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports the development of a GMP-compliant E. coli dihydrofolate reductase (EDHFR) vector. This vector will be used to monitor the biodistribution and trafficking of investigational chimeric antigen receptor (CAR) T cell therapies through positron emission tomography (PET) imaging. The goals are to provide a...
- This $3,170,096 Project Grant was awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research federal grant program (CFDA 93.855). The grant supports research to develop the L7AE protein as a therapeutic for treating infections caused by the Orthomyxoviridae virus family, which includes influenza. The key research aims are: (1) investigating the mechanism of action of L7AE on various Orthomyxoviridae family members, (2)...
- This federal Project Grant award of $299,954 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports the development of L2 Diagnostics LLC's novel malaria vaccine candidate called PFAG. The project aims to (i) optimize the PFAG vaccine construct and (ii) conduct efficacy testing to confirm the optimal design. PFAG is a multivalent peptide vaccine composed of synthetic peptides representing...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $299,163 Project Grant to Phase Genomics Inc. under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855). The project aims to establish a novel antimicrobial approach that combines endolysin proteins from Phase Genomics' metagenomic database with self-replicating mRNA (repRNA) delivery using lipid nanoparticles. The Phase I proof-of-concept study has two key objectives: 1) evaluate whether...
- This $392,634 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports the development of a novel nanoimmunotherapeutic approach to combat multidrug-resistant (MDR) bacterial infections. The project aims to design, fabricate, and optimize a red blood cell membrane-coated, hemoglobin-encapsulating nanoparticle (RHNP) that can sensitize bacteria to host oxidant killing while...